-DOCSTART- -X- O
Zika -X- _ B-Patient
virus -X- _ I-Patient
is -X- _ O
an -X- _ O
emergent -X- _ O
pathogen -X- _ O
that -X- _ O
gained -X- _ O
significant -X- _ O
importance -X- _ O
during -X- _ O
the -X- _ O
epidemic -X- _ O
in -X- _ O
South -X- _ O
and -X- _ O
Central -X- _ O
America -X- _ O
as -X- _ O
unusual -X- _ O
and -X- _ O
alarming -X- _ O
complications -X- _ O
of -X- _ O
infection -X- _ O
were -X- _ O
recognized. -X- _ O
Although -X- _ O
initially -X- _ O
considered -X- _ O
a -X- _ O
self-limited -X- _ O
benign -X- _ O
infection -X- _ O
, -X- _ O
a -X- _ O
panoply -X- _ O
of -X- _ O
neurologic -X- _ O
complications -X- _ O
were -X- _ O
recognized -X- _ O
including -X- _ O
a -X- _ O
Guillain–Barré-like -X- _ O
syndrome -X- _ O
and -X- _ O
in-utero -X- _ O
fetal -X- _ O
infection -X- _ O
causing -X- _ O
microcephaly -X- _ O
, -X- _ O
blindness -X- _ O
, -X- _ O
and -X- _ O
other -X- _ O
congenital -X- _ O
neurologic -X- _ O
complications. -X- _ O
Numerous -X- _ O
Zika -X- _ B-Intervention
virus -X- _ I-Intervention
vaccines -X- _ I-Intervention
were -X- _ O
developed -X- _ O
, -X- _ O
with -X- _ O
nine -X- _ B-Outcome
different -X- _ I-Outcome
vaccines -X- _ I-Outcome
representing -X- _ I-Outcome
five -X- _ I-Outcome
different -X- _ I-Outcome
platforms -X- _ I-Outcome
entered -X- _ I-Outcome
into -X- _ I-Outcome
clinical -X- _ I-Outcome
trials -X- _ I-Outcome
, -X- _ I-Outcome
one -X- _ I-Outcome
progressing -X- _ I-Outcome
to -X- _ I-Outcome
Phase -X- _ I-Outcome
II. -X- _ I-Outcome
Here -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
landscape -X- _ O
and -X- _ O
challenges -X- _ O
confronting -X- _ O
Zika -X- _ B-Intervention
virus -X- _ I-Intervention
vaccine -X- _ I-Intervention
development -X- _ O
. -X- _ O

